Zoetis Inc. A Stock
€173.12
Your prediction
Zoetis Inc. A Stock
Pros and Cons of Zoetis Inc. A in the next few years
Pros
Cons
Performance of Zoetis Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. A | -2.740% | 2.657% | 6.218% | 5.271% | -0.472% | 4.586% | 58.396% |
| Johnson & Johnson | -1.200% | 0.013% | 3.457% | -1.566% | 5.664% | 6.552% | 26.561% |
| Elanco Animal Health Inc. | -1.330% | -0.850% | -1.597% | 18.297% | -3.402% | -52.733% | - |
| Biogen Inc. | 1.070% | -1.550% | -2.867% | -24.958% | -24.576% | -30.487% | -16.561% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.
Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.
EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.
Comments
News
Zoetis (ZTS) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q2 2024 Earnings CallAug 06, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Zoetis Stock Was Moving Higher Tuesday
Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical maker, were climbing today after the company reported better-than-expected results in its second-quarter earnings report and raised
Beat the Dow Jones With This Cash-Gushing Dividend Stock
Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal